
Supplementary information

Neurodevelopmental comorbidities in juvenile systemic autoimmune and autoinflammatory diseases

**In the format provided by
the authors and unedited**

Supplementary Table 1:

Juvenile autoimmune and autoinflammatory diseases associated with neurological features, neuroinflammation and/or neurodevelopment disorders.

Juvenile auto-immune and auto-inflammatory diseases (OMIM if relevant)	Implicated Gene(s)	Other clinical features	Neurologic features - Neuroinflammation	NDD	Ref
Auto-inflammation					
Type I interferonopathies					
AGS1 (225750), chilblain lupus (610448), SLE (152700)	<i>TREX1</i>	Chilblain lupus, SLE	AGS - most severe	Global developmental delay	¹
AGS4 (610333)	<i>RNASEH2A</i>		AGS	Global developmental delay	¹
AGS2 , spastic paraparesis (610181)	<i>RNASEH2B</i>	Chilblain lupus, SLE	AGS - least severe, jNPSLE	Global developmental delay	^{1,2}
AGS3 (610329)	<i>RNASEH2C</i>		AGS	Global developmental delay	¹
AGS5 , cerebrovascular disease (612952), chilblain lupus (614415)	<i>SAMHD1</i>	Chilblain lupus	AGS, cerebrovascular disease (Moya-Moya)	Global developmental delay	¹
AGS6 , bilateral striatal necrosis (615010), dyschromatosis symmetrica hereditaria (127400)	<i>ADAR1</i>	Dyschromatosis symmetrica hereditaria	AGS, bilateral striatal necrosis	Global developmental delay	¹
AGS7 , spastic paraparesis, NMO (615846), SMS (182250)	<i>MDA5</i>	SMS	AGS, spastic paraparesis, NMO	Global developmental delay	¹
Ataxia telangiectasia (208900)	<i>ATM</i>	Telangiectasia, primary immunodeficiency	Ataxia, eye movement abnormalities, movement disorders	Mild to moderate developmental delay, cognitive impairment	^{1,3,4}
AGS-like, bilateral striatal necrosis (610316)	<i>PNPT1</i>		AGS, bilateral striatal necrosis, some Leigh syndrome, Ataxia, seizures, neuropathy, hearing-loss, nystagmus, hypotonia	Global developmental delay	^{1,5}
ATAD3A deficiency (617183)	<i>ATAD3A</i>	Systemic sclerosis (SSc), vitiligo, hypertrophic cardiomyopathy	Spastic paraparesis, dystonia, elevated CSF neopterin, peripheral neuropathy	Global development delay	^{1,6}
AGS8 (619486)	<i>LSM11</i>		AGS	Global development delay	¹
AGS9 (619487)	<i>U7 (RNU7-1)</i>		AGS	Global development delay	¹
ARF1 deficiency (103180)	<i>ARF1</i>	Chilblain lupus	AGS-like, periventricular nodular heterotopia (PVNH)	Global development delay, delays in motor skills and speech, oral-motor coordination difficulties	¹
STAT2 loss of negative regulation (600556)	<i>STAT2</i>	Severe fatal early-onset autoinflammation	AGS-like, spastic paraparesis / dystonic tetraparesis	Global development delay	^{1,7,8}
Immunodeficiency with basal ganglia calcification (616126)	<i>ISG15</i>	MSMD	Seizures and ICC	Global development delay	¹
USP18 deficiency (617397)	<i>USP18</i>	Autoinflammation and mycobacterial disease	AGS-like / TORCH-like syndrome, seizures, encephalopathy, polymicrogyria	Global developmental delay	^{1,8,9}
Trisomy 21	Trisomy of chromosome 21	Auto-immune predisposition	Down syndrome, ICC, Regression syndrome with catatonia	Global development delay, Regression syndrome	¹
TLR7 GOF (300365)	<i>TLR7</i>	(j)SLE	NMO, ICC, NPSLE, seizures	Mild motor developmental delay	^{1,10}
Leukoencephalopathy cystic without megalencephaly (612951)	<i>RNASET2</i>	Autoinflammation	AGS-like, TORCH pseudo-CMV disease, encephalopathy	Global developmental delay	¹
DADA2 (615688)*	<i>ADA2</i>	Autoinflammation, vasculitis, cytopenias, immunodeficiency	Cerebrovasculitis with strokes	Neurocognitive disorders, ASD, ADHD	^{1,11,12}
SPENCD (607944)	<i>ACP5</i>	SLE, short stature, thrombocytopenia and AIHA	ICC, spastic paraparesis	Mild to moderate developmental delay	^{1,13,14}
Complement deficiencies** (613652, 620321, 620322)	<i>C1QA, C1QB, C1QC</i>	jSLE, susceptibility to encapsulated organisms/immunodeficiency	jNPSLE, seizures, AGS-like, cerebrovascular disease	Global developmental delay	^{1,15}
Complement deficiencies** (216950)	<i>C1r</i>	jSLE, susceptibility to encapsulated organisms/immunodeficiency	jNPSLE	NA	^{1,16}
Complement deficiencies** (614380)	<i>C4A</i>	jSLE, susceptibility to encapsulated organisms/immunodeficiency	Cerebral vasculitis, seizures	NA	^{1,17}
PRAAS1 (256040)	<i>PSMB8</i>	Contractures, panniculitis, recurrent fever	ICC, aseptic meningitis	NA	^{8,18}
PRAAS6 (617591)	<i>PSMB9</i>	Skin rash, recurrent fever, anaemia, elevated LFTs, myositis (elevated CK), pulmonary hypertension	Seizures and ICC	NA	¹⁹

PRAAS2 / PRAID (618048)	<i>POMP</i>	Chronic atypical neutrophilic dermatitis with lipodystrophy, ILD	Seizures	NA	20
Stankiewicz-Isidor syndrome (617516)	<i>PSMD12</i>	Urticarial skin rash, autoinflammation		Global developmental delay, ASD	8,21,22
PTPN1 haploinsufficiency	<i>PTPN1</i>	Raised LFTs, recurrent fever	Subacute spastic dystonia, encephalopathy	Rare mild motor delay, regression	23
DNASE II deficiency (619858)	<i>DNASE2</i>	Recurrent fevers, neonatal HSM and pancytopenia	NA	Global developmental delay (learning difficulties)	24
Inflammasomopathies					
FMF (249100)	<i>MEFV</i>	FMF	Headaches, seizures, peripheral neuropathy, demyelinating disorders, cerebrovascular disease	Inattention, hyperactivity, ADHD, specific learning disorders	25–27
PAANI	<i>MEFV</i> (E583A)	Autoinflammation (fever, chest/abdominal/muscle pain, orchitis)	Seizures, aseptic meningitis	NA	28,29
CAPS (607115)	<i>NLRP3</i>	Urticarial rash, hearing loss, arthritis	Chronic aseptic meningitis, headaches, hearing loss, visual impairment	Severe intellectual disability	30,31
Majeed syndrome (609628)	<i>LPIN2</i>	CRMO, anaemia, failure to thrive	Irritability	Delayed motor milestones	32
MKD (260920, 610377)	<i>MVK</i>	Periodic fever, gastro-intestinal features, MKD	Headaches, cerebellar ataxia, seizures, allodynia, cerebral atrophy, paralysis, seizures, stroke, tremor, and meningitis	Mental or motor retardation, language disorder	33,34
NLRP12-related AID or FCAS2 (611762)	<i>NLRP12</i>	Nonpruritic urticaria, arthritis, fever	Headaches, sensorineural hearing loss	NA	35
DIRA (612852)	<i>IL1RN</i>	Neonatal CRMO, periostitis, pustulosis	Aseptic meningitis, sensorineural deafness	Global developmental delay	36
NLRC4 associated AID or FCAS4 (616115, 616050)	<i>NLRC4</i>	MAS, urticarial rash / FCAS	Aseptic meningitis, sensorineural deafness	Brain atrophy, mental retardation	37
H syndrome (602782)	<i>SLC29A3</i>	Hyperpigmentation, hypertrichosis, HSM, heart anomalies, hypogonadism, low height, diabetes mellitus, recurrent fever	Sensorineural deafness	Global developmental delay	38
X-linked proliferative disease 2 (300079)	<i>XIAP</i>	EBV infection, splenomegaly, lymphoproliferation, HLH, colitis, IBD, hepatitis	CNS vasculitis	Dementia	8,39,40
NF-kB-pathies					
HA20*** (616744)	<i>TNFAIP3</i>	Bipolar aphtous ulceration, Behcet's disease-like, uveitis, joint pain, JSLE-like	Neuro-Behçet's disease, CNS vasculitis, seizures	Global development delay	41,42
RAID or Rela haploinsufficiency*** (618287)	<i>RelA</i>	IBD-like, Behcet's disease-like, JIA-like and JSLE-like	NMO	NA	8,43
Blau Syndrome (186580)****	<i>NOD2</i>	Blau syndrome, early onset sarcoidosis	Granulomatous CNS involvement	NA	44
TBK1 deficiency (620880)	<i>TBK1</i>	Chronic systemic autoinflammation, polyarthritis, vasculitis, rash	Seizures	Global developmental delay (delayed cognitive development)	45
ROSAH syndrome (614979)	<i>ALPK1</i>	Retinal dystrophy, splenomegaly, anhidrosis, recurrent fever, arthritis, colitis, dental abnormalities, uveitis	Optic nerve oedema, headache, migraine, premature CNS mineralisation, Focal meningeal enhancement, neuro-Behçet's disease-like, multiple sclerosis-like	NA	8,46
NEMO-NDAS (301081)	<i>IKBKG</i>	Recurrent fever, skin rash, systemic autoinflammation, infection, panniculitis, uveitis, HSM, ectodermal dysplasia	CNS involvement (CNS bleed)	NA	8
SOCS1 haploinsufficiency 619375)	<i>SOCS1</i>	Early-onset autoimmunity, cytopenia, HSM, SLE, arthritis	Seizures, limbic encephalitis, MS	Delayed psychomotor development	47
Actin Cytoskeletonopathies					
CDC42 deficiency / NOCARH syndrome (616737) ***	<i>CDC42</i>	Pancytopenia, fever, rash, hepatosplenomegaly, systemic inflammation, myelofibrosis, HLH, enterocolitis, failure to thrive	CNS inflammatory disease	Neurodevelopmental delay	8,48,49
Others					
DADA2* (607575)	<i>CECR1</i>	Autoinflammation, vasculitis, cytopenias, immunodeficiency	Cerebrovasculitis with strokes	Neurocognitive disorders, ASD, ADHD	8,11
SIFD (612907)	<i>TRNT1</i>	Congenital sideroblastic anaemia	Seizures, sensorineural hearing loss, CNS malformations	Global development delay	8,50

VEXAS (NA)	<i>UBA1</i>	Fatigue, recurrent fever, neutrophilic dermatosis, chondritis, myelodysplastic syndrome	6-7,8% CNS manifestations (optic neuritis, aseptic meningitis, inflammatory pseudotumor, CNS vasculitis and rhombencephalitis, PRES)	NA	51,52
Prolidase deficiency (613230)	<i>PEPD</i>	Ulcerative skin disease, telangiectasia, HSM, recurrent fever, MAS	Seizures, neuropathy, WM abnormalities	Variable global development delay	53
NASA (607676)	<i>IRAK4</i>	Recurrent fever, splenomegaly, elevated inflammatory markers, hypochromic microcytic anaemia	Seizures, suspected meningoencephalitis, elevated CSF IL-6	NA	8
Autoimmunity					
jSLE					
Multifactorial jSLE	None	jSLE	jNPSLE	Learning disabilities	54
jSLE/Complement deficiencies**	See above				
X-linked jSLE (NA)	<i>SAT1</i>	jSLE	jNPSLE	NA	55
TLR7 GOF (300365)	<i>TLR7</i>	(j)SLE	NMO, ICC, jNPSLE, seizures	Mild motor developmental delay	1,10
NFkB-pathies***	See above				
JDM					
NXP2 JDM	None	JDM	Seizures, CNS vasculitis	NA	56
JIA					
JIA (different subtypes)	None		Exceptional: Seizures, headaches, cerebellitis, cerebral vasculitis, aseptic meningitis, NMDA encephalitis	ADHD, cognitive deficits	54
Vasculitis					
KD - MIS-C	None (<i>OAS1-RNASE L</i>)	Kawasaki disease / MIS-C	Acute aseptic meningitis, headaches, irritability, confusion, cerebellitis	Memory impairment, cognitive impairment	57,58
Multifactorial juvenile Behçet's disease	None	Bipolar ulcerations, uveitis,	Neuro-Behçet's disease	Development delay secondary to inflammation	59,60
Multifactorial vasculitis	None	Systemic vasculitis	CNS vasculitis		61
Sarcoidosis					
Multifactorial juvenile Sarcoidosis	None	Granulomatous disease, granulomatous uveitis	Neuro-sarcoidosis		62
Blau Syndrome (186580)****	See above				

AGS: Aicardi-Goutières syndrome; CAPS: Cryopyrin-associated periodic syndromes; CNS: central nervous system; DADA2: adenosine deaminase 2 deficiency; DIRA: deficiency of the interleukin 1 (IL-1) receptor antagonist; FCAS: familial cold-autoinflammatory syndrome; FMF: familial Mediterranean fever; GOF: gain of function; ICC: intracranial calcifications; HA20: haploinsufficiency in A20; JDM: juvenile dermatomyositis; JIA: juvenile idiopathic arthritis; jNPSLE: juvenile neuro-psychiatric systemic lupus erythematosus; jSLE: juvenile systemic lupus erythematosus; KD: Kawasaki disease; MIS-C: multisystem inflammatory syndrome in children; MKD: mevalonate kinase deficiency; MS: multiple sclerosis; NA: not available; NASA: systemic autoinflammation splenomegaly and anaemia; NEMO-NDAS: NEMO deleted exon 5 autoinflammatory syndrome; NMO: neuromyelitis optica; NOCARH: neonatal onset of cytopenia, autoinflammation, rash, and hemophagocytosis; PAANI: pyrin-associated autoinflammatory disease with neuroinflammation; PRAAS: Proteasome-associated autoinflammatory syndrome; ROSAH: retinal dystrophy, optic nerve oedema, splenomegaly, anhidrosis, and migraine headache; SIFD: congenital sideroblastic anaemia with immunodeficiency, fevers, and developmental delay; SMS: Singleton-Merten syndrome; VEXAS: vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome; WM: white matter.

References:

1. Crow, Y. J. CNS disease associated with enhanced type I interferon signalling. *Lancet Neurol.* **23**, 1158–1168 (2024).
2. Ayrolles, A. *et al.* Catatonia in a patient with Aicardi-Goutières syndrome efficiently treated with immunoadsorption. *Schizophr. Res.* **222**, 484–486 (2020).
3. Hoche, F. *et al.* Cognitive phenotype in ataxia-telangiectasia. *Pediatr. Neurol.* **51**, 297–310 (2014).
4. Vinck, A. *et al.* Cognitive and speech-language performance in children with ataxia telangiectasia. *Dev. Neurorehabilitation* **14**, 315–322 (2011).
5. Rius, R. *et al.* Clinical Spectrum and Functional Consequences Associated with Bi-Allelic Pathogenic PNPT1 Variants. *J. Clin. Med.* **8**, 2020 (2019).
6. Lepelley, A. *et al.* Enhanced cGAS-STING-dependent interferon signaling associated with mutations in ATAD3A. *J. Exp. Med.* **218**, e20201560 (2021).
7. Zhu, G. *et al.* Type I Interferonopathy due to a Homozygous Loss-of-Inhibitory Function Mutation in STAT2. *J. Clin. Immunol.* **43**, 808–818 (2023).
8. Poli, M. C. *et al.* Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee. *J. Hum. Immun.* **1**, e20250003 (2025).

9. Meuwissen, M. E. C. *et al.* Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. *J. Exp. Med.* **213**, 1163–1174 (2016).
10. David, C. *et al.* Interface Gain-of-Function Mutations in TLR7 Cause Systemic and Neuro-inflammatory Disease. *J. Clin. Immunol.* **44**, 60 (2024).
11. Dzhus, M. *et al.* A Narrative Review of the Neurological Manifestations of Human Adenosine Deaminase 2 Deficiency. *J. Clin. Immunol.* **43**, 1916–1926 (2023).
12. Lee, P. Y. *et al.* Evaluation and Management of Deficiency of Adenosine Deaminase 2: An International Consensus Statement. *JAMA Netw. Open* **6**, e2315894 (2023).
13. Briggs, T. A. *et al.* Spondyloenchondrodysplasia Due to Mutations in ACP5: A Comprehensive Survey. *J. Clin. Immunol.* **36**, 220–234 (2016).
14. Elhossini, R. M., Elbendary, H. M., Rafat, K., Ghorab, R. M. & Abdel-Hamid, M. S. Spondyloenchondrodysplasia in five new patients: identification of three novel ACP5 variants with variable neurological presentations. *Mol. Genet. Genomics MGG* **298**, 709–720 (2023).
15. Triaille, C. *et al.* Hereditary C1q Deficiency is Associated with Type 1 Interferon-Pathway Activation and a High Risk of Central Nervous System Inflammation. *J. Clin. Immunol.* **44**, 185 (2024).
16. Demirkaya, E. *et al.* Brief Report: Deficiency of Complement 1r Subcomponent in Early-Onset Systemic Lupus Erythematosus: The Role of Disease-Modifying Alleles in a Monogenic Disease. *Arthritis Rheumatol.* **69**, 1832–1839 (2017).
17. Lhotta, K. *et al.* Cerebral vasculitis in a patient with hereditary complete C4 deficiency and systemic lupus erythematosus. *Lupus* **13**, 139–141 (2004).
18. Al-Mayouf, S. M. *et al.* Monogenic interferonopathies: Phenotypic and genotypic findings of CANDLE syndrome and its overlap with C1q deficient SLE. *Int. J. Rheum. Dis.* **21**, 208–213 (2018).
19. Kataoka, S. *et al.* Successful treatment of a novel type I interferonopathy due to a de novo PSMB9 gene mutation with a Janus kinase inhibitor. *J. Allergy Clin. Immunol.* **148**, 639–644 (2021).
20. Poli, M. C. *et al.* Heterozygous Truncating Variants in POMP Escape Nonsense-Mediated Decay and Cause a Unique Immune Dysregulatory Syndrome. *Am. J. Hum. Genet.* **102**, 1126–1142 (2018).
21. Yan, K. *et al.* Haploinsufficiency of PSMD12 Causes Proteasome Dysfunction and Subclinical Autoinflammation. *Arthritis Rheumatol.* **74**, 1083–1090 (2022).
22. Khalil, R. *et al.* PSMD12 haploinsufficiency in a neurodevelopmental disorder with autistic features. *Am. J. Med. Genet. Part B Neuropsychiatr. Genet. Off. Publ. Int. Soc. Psychiatr. Genet.* **177**, 736–745 (2018).
23. Zhu, G. *et al.* Autoinflammatory encephalopathy due to PTPN1 haploinsufficiency: a case series. *Lancet Neurol.* **24**, 218–229 (2025).
24. Rodero, M. P. *et al.* Type I interferon-mediated autoinflammation due to DNase II deficiency. *Nat. Commun.* **8**, 2176 (2017).
25. Silva, G. D. *et al.* Identifying high-risk neurological phenotypes in adult-onset classic monogenic autoinflammatory diseases: when should neurologists consider testing? *BMC Neurol.* **24**, 130 (2024).
26. Lavi, E. *et al.* Increased prevalence of attention-deficit hyperactivity disorder symptomatology in patients with familial Mediterranean fever. *Mod. Rheumatol.* **32**, 422–426 (2022).
27. La Bella, S. *et al.* Neurological involvement in children with familial Mediterranean fever: a systematic review. *Pediatr. Rheumatol. Online J.* **23**, 90 (2025).
28. Wang, Q. *et al.* A dominant pathogenic MEFV mutation causes atypical pyrin-associated periodic syndromes. *JCI Insight* **8**, e172975 (2023).
29. Mertz, P., Boursier, G., Hentgen, V. & Georgin-Lavialle, S. New Diseases Linked to MEFV Variants or Pyrinopathies. *J. Allergy Clin. Immunol. Pract.* **13**, 522–532 (2025).
30. Mamoudjy, N., Maurey, H., Marie, I., Koné-Paut, I. & Deiva, K. Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS). *Orphanet J. Rare Dis.* **12**, 33 (2017).
31. Levy, R. *et al.* Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. *Ann. Rheum. Dis.* **74**, 2043–2049 (2015).
32. Chavan, P. P. *et al.* Majeed Syndrome: Five Cases With Novel Mutations From Unrelated Families in India With a Review of Literature. *J. Rheumatol.* **48**, 1850–1855 (2021).
33. Ter Haar, N. M. *et al.* The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. *Arthritis Rheumatol.* **68**, 2795–2805 (2016).
34. Boursier, G., Rittore, C., Milhavet, F., Cuisset, L. & Touitou, I. Mevalonate Kinase-Associated Diseases: Hunting for Phenotype-Genotype Correlation. *J. Clin. Med.* **10**, 1552 (2021).
35. Kostik, M. M. *et al.* Multigene sequencing reveals heterogeneity of NLRP12-related autoinflammatory disorders. *Rheumatol. Int.* **38**, 887–893 (2018).
36. Goldbach-Mansky, R. *et al.* Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. *N. Engl. J. Med.* **355**, 581–592 (2006).
37. Kawasaki, Y. *et al.* Identification of a High-Frequency Somatic NLRC4 Mutation as a Cause of Autoinflammation by Pluripotent Cell-Based Phenotype Dissection. *Arthritis Rheumatol.* **69**, 447–459 (2017).
38. Melki, I. *et al.* Mutation in the SLC29A3 gene: a new cause of a monogenic, autoinflammatory condition. *Pediatrics* **131**, e1308–1313 (2013).

39. Talaat, K. R. *et al.* Lymphocytic vasculitis involving the central nervous system occurs in patients with X-linked lymphoproliferative disease in the absence of Epstein-Barr virus infection. *Pediatr. Blood Cancer* **53**, 1120–1123 (2009).
40. Blackburn, P. R. *et al.* X-Linked Lymphoproliferative Syndrome Presenting as Adult-Onset Multi-Infarct Dementia. *J. Neuropathol. Exp. Neurol.* **78**, 460–466 (2019).
41. Shirai, H. *et al.* Case report: Adult case of A20 haploinsufficiency suspected as neuro-Behçet disease. *Front. Immunol.* **15**, 1508307 (2024).
42. Philip, R. *et al.* A20 haploinsufficiency diagnosis beyond systemic lupus erythematosus: A systematic review of the literature. *Autoimmun. Rev.* **24**, 103722 (2025).
43. Adeeb, F. *et al.* A Novel RELA Truncating Mutation in a Familial Behçet's Disease-like Mucocutaneous Ulcerative Condition. *Arthritis Rheumatol.* **73**, 490–497 (2021).
44. Goyal, M., Cohen, M. L., Bangert, B. A., Robinson, S. & Singer, N. G. Rasmussen syndrome and CNS granulomatous disease with NOD2/CARD15 mutations. *Neurology* **69**, 640–643 (2007).
45. Taft, J. *et al.* Human TBK1 deficiency leads to autoinflammation driven by TNF-induced cell death. *Cell* **184**, 4447–4463.e20 (2021).
46. Kozycki, C. T. *et al.* Gain-of-function mutations in ALPK1 cause an NF-κB-mediated autoinflammatory disease: functional assessment, clinical phenotyping and disease course of patients with ROSAH syndrome. *Ann. Rheum. Dis.* **81**, 1453–1464 (2022).
47. Palmeri, S. *et al.* Neurological Phenotypes of SOCS1 Haploinsufficiency: Insights from Functional and Histological Investigations. *J. Clin. Immunol.* **45**, 165 (2025).
48. Lam, M. T. *et al.* A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. *J. Exp. Med.* **216**, 2778–2799 (2019).
49. Yasumi, T. CDC42 missense mutations and human diseases: from neurodevelopmental disorders to autoinflammation. *J. Biochem. (Tokyo)* **178**, 73–78 (2025).
50. Chakraborty, P. K. *et al.* Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). *Blood* **124**, 2867–2871 (2014).
51. Al-Hakim, A. *et al.* Clinical features in VEXAS syndrome: a systematic review. *Rheumatology* **64**, 5217–5229 (2025).
52. Bert-Marcaz, C. *et al.* Neurological manifestations in patients with VEXAS syndrome. *J. Neurol.* **272**, 181 (2025).
53. Rossignol, F. *et al.* Quantitative analysis of the natural history of prolidase deficiency: description of 17 families and systematic review of published cases. *Genet. Med. Off. J. Am. Coll. Med. Genet.* **23**, 1604–1615 (2021).
54. Yıldırım, M., Altıntaş, M., Tabanlı, F. P., Bektaş, Ö. & Teber, S. Central Nervous System Involvement in Pediatric Juvenile Idiopathic Arthritis: A Case Report of Cerebellitis and Literature Review. *J. Child Neurol.* **40**, 478–485 (2025).
55. Xu, L. *et al.* Loss-of-function variants in SAT1 cause X-linked childhood-onset systemic lupus erythematosus. *Ann. Rheum. Dis.* **81**, 1712–1721 (2022).
56. Yang, L. *et al.* Juvenile dermatomyositis with central nervous system involvement: two case reports from a retrospective single-center cohort, with literature review. *Front. Pediatr.* **12**, 1409950 (2024).
57. Lee, D. *et al.* Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children. *Science* **379**, eabo3627 (2023).
58. Mauro, A. *et al.* Neurological manifestations of Kawasaki disease and multisystem inflammatory syndrome in children associated with COVID-19: A comparison of two different clinical entities. *Front. Pediatr.* **10**, 1088773 (2022).
59. Matucci-Cerinic, C. *et al.* Validation of the PEDiatric Behçet's Disease classification criteria: an evidence-based approach. *Rheumatology* **63**, 3422–3431 (2024).
60. Kidd, D. P. Neurological involvement by Behçet's syndrome: clinical features, diagnosis, treatment and outcome. *Pract. Neurol.* **23**, 386–400 (2023).
61. Nie, N. *et al.* Eosinophilic granulomatous polyangiitis with central nervous system involvement in children: a case report and literature review. *Front. Immunol.* **15**, 1406424 (2024).
62. Tohme, R. *et al.* Diagnostic and Therapeutic Insights Into Pediatric Neurosarcoidosis: Observations From French Pediatric Rheumatology Centers. *Pediatr. Neurol.* **162**, 12–20 (2025).